Michael Dixon
OMAHA, Neb. (Sept. 13, 2016)—UNeMed president and CEO Michael Dixon will be among the featured speakers this week when the University of Nebraska Medical Center hosts its third annual Biopharmaceutical Research & Development Symposium.
The symposium will be held at UNMC’s Lozier Center for Pharmacy and Education, located at 4040 Emile Street. The event kicks off with a full day of presentations on Wednesday, Sept. 14, beginning at 8:45 a.m. The event concludes the following day at about 12:45 p.m.
Dr. Dixon is expected to address attendees just before lunch on the first day, taking on the “Role of Intellectual Property in Drug Discovery and Development” at 11:15 a.m.
An effort to promote and improve collaborations between academic researchers and industrial organizations, the Biopharmaceutical Research & Development Symposium will feature more than a dozen drug development researchers and industry insiders. Among the featured speakers are guests from Pfizer, Harvard University and the Food and Drug Administration, to name a few.
According to its website, the stated goal of the symposium is to “highlight state-of-the-art practices in the pharmaceutical industry’s discovery and development of new drugs” and help produce a “guide to successful industry-academia collaboration with the opportunity to explore scale-up challenges and collaborate on how academia can more closely model industry level pharmaceutical processes.”
Topics to be covered are:
- Chemistry of Therapeutic Oligonucleotides
- Small Molecules as Tools to modulate miRNAs and other Noncoding RNAs
- Nucleic Acid-Based Drug Modalities: Developing New Classes of Drugs
- NIH Funding on Nanomedicines and Gene Therapy Research
- Gene Therapy for Tissue Regeneration
- Challenges and Opportunities in the Clinical Translation of Nucleic Acid Therapeutics
- Drug Metabolism and Pharmacokinetics of macromolecules (eg ADC)
- miRNAs as Therapeutic targets in Breast Cancer
- Development of MRG-106, an Oligonucleotide Inhibitor of miR-155, for Hematological Malignancies
- Role of Biopharmaceutics in Drug Development and Regulation
- Role of Intellectual Property in Drug Discovery and Development
- Targeting PLP-Enzymes for Mechanism-Based Inhibition-from Fundamental Studies to Lead Compounds for Therapeutics
Learn more about the symposium at: https://www.unmc.edu/pharmacy/programs/symposium/program.html
